MVR-T7013

N/A

Report date: 2025/02/08 16:20:29

Base Information

Drug NameMVR-T7013
Drug Alias NameCD19/HER2/IL-12/CCL5/PD-1 Checkpoint Inhibitor-Expressing Oncolytic HSV Therapy (ImmVira)MVR-T7013
ClassificationBiologics > Protein drugs > Immunoglobulin > AntibodyBiologics > Oncolytic virus
Mechanisms of ActionC-C chemokine receptor type 5 agonistsReceptor protein-tyrosine kinase erbB-2 modulatorsProgrammed cell death protein 1 blockers +[5] 
TargetsB-lymphocyte antigen CD19Interleukin-12 receptorC-C chemokine receptor type 5 +[5] 
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesImmvira Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesImmvira Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A